Treatment of Cryptococcosis in Immunocompromised Patients

Initial Treatment Approach

The Infectious Diseases Society of America recommends amphotericin B (0.7-1 mg/kg/day IV) plus flucytosine (100 mg/kg/day orally in 4 divided doses) for 2 weeks as induction therapy, followed by fluconazole (400 mg/day) for a minimum of 10 weeks as consolidation therapy, and then fluconazole (200 mg/day) lifelong as maintenance therapy for the treatment of cryptococcemia in AIDS patients 1, 2, 3
For patients with renal impairment, liposomal amphotericin B (AmBisome) 4 mg/kg/day can be substituted for conventional amphotericin B 4
Blood cultures should be obtained to confirm clearance of cryptococcemia 5
A lumbar puncture must be performed to rule out CNS involvement, as Cryptococcus has a strong predilection for the CNS 6

Monitor renal function, electrolytes, and complete blood counts regularly, especially during amphotericin B therapy 3
For patients receiving flucytosine, monitor serum levels (optimal: 30-80 mg/mL) and adjust dosage based on renal function 1, 2
Treatment decisions should not be based exclusively on cryptococcal antigen titers in serum 8
The American College of Physicians recommends initiating or optimizing antiretroviral therapy as part of the comprehensive management of cryptococcosis in AIDS patients 7

After consolidation therapy, continue with fluconazole 200-400 mg/day orally as lifelong suppressive therapy 7, 1, 2
Fluconazole is superior to itraconazole and amphotericin B for maintenance therapy, with relapse rates significantly lower (2-3%) compared to other regimens 7